BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
The Indian pharma market declined 2.2% in August 2020.
The drop in acute therapies continues to exert pressure on industry growth while growth in select chronic therapies such as cardiac continues in double digits.
Industry volume growth continues to suffer; on a higher base (good anti-infective season last year) August 2020 volumes were down 9.2% while blended price growth was 4.4%; new product growth, 2.5%.
Chronic therapies continues to lead the growth. Cardio grew 12% to Rs 17 billion in August and remains the largest therapy in India for the second straight month (moving annual total sales of Rs 191 billion versus Rs 186 billion for anti infectives).
Other chronic therapies such as vitamins grew 6%; diabetes sales were up 2%.
The fall in sales of acute therapies such as anti-infectives (down 11%), Ophthal (14%) and Pain (10%) continued for yet another month.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR